Search clinical trials for: Placebo for LIPO-202

Total 3104 results

Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
Neothetics, Inc

Unknown

An Open-Label Study to Evaluate Retreatment With LIPO-202

Central Abdominal Bulging

United States
Neothetics, Inc

Completed

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

Subcutaneous Abdominal Adiposity

United States
Neothetics, Inc

Completed

Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)

Thyroid-Related Eye Disease

Australia, New Zealand
Neothetics, Inc

Completed

Dose Ranging and Dose Frequency of LIPO-102

Subcutaneous Adipose Tissue Reduction

United States
Neothetics, Inc

Completed

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Subcutaneous Adipose Tissue Reduction

United States
Neothetics, Inc

Completed

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Submental Fat

United States
Neothetics, Inc

Completed

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Central Abdominal Bulging

United States
Evofem Inc.
Neothetics, Inc

Completed

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Central Abdominal Bulging

United States
Neothetics, Inc

Completed

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR1)

Central Abdominal Bulging

United States
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
CuraSen Therapeutics, Inc.

Completed

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Dementia | Mild Cognitive Impairment

United States, New Zealand
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
Fab'entech

Recruiting

Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

COVID-19

Greece
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Hyundai Pharm

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

Contraception

Korea, Republic of
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
Akron Molecules AG

Completed

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Osteoarthritis

Austria
Akros Pharma Inc.

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Diabetes Mellitus

United States
CinDome Pharma, Inc.

Terminated

A Scintigraphy Study in Adults With Diabetic Gastroparesis

Diabetic Gastroparesis

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
Theraclone Sciences, Inc.

Completed

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Cytomegalovirus Infections

United States
Radboud University Medical Center
GlaxoSmithKline

Completed

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Influenza | Herpes Zoster

Netherlands
Northwestern University
Brain & Behavior Research Foundation; Neurocentria, Inc.

Completed

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Bial - Portela C S.A.

Completed

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Parkinson's Disease

United Kingdom
9 Meters Biopharma, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

Celiac Disease

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

Biomarker

United Kingdom
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom
Inversago Pharma Inc.
Worldwide Clinical Trials

Active, not recruiting

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Diabetic Kidney Disease

United States, Israel, Canada, Georgia, Hungary, Serbia, Mexico
Bial - Portela C S.A.

Completed

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Parkinson's Disease

Portugal
Neothetics, Inc

Completed

Dose Ranging Study (RESET)

Periumbilical Subcutaneous Adipose Tissue Reduction

United States
ANRS, Emerging Infectious Diseases

Completed

Lipopeptide Immunisation With GTU-multiHIV Trial

HIV-1 Infection

France
TenNor Therapeutics Inc.

Completed

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) | Prosthetic Joints Infection (PJI)

China
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Acute Upper Respiratory Infections

Russian Federation
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Arxx Therapeutics

Recruiting

A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Healthy Volunteers | Mild to Moderate Psoriasis

United Kingdom
9 Meters Biopharma, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

Celiac Disease

United States, Canada, Spain
9 Meters Biopharma, Inc.
Teva Pharmaceuticals USA

Completed

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Celiac Disease

United States, Canada
9 Meters Biopharma, Inc.

Completed

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

Celiac Disease

United States
Hams Hamed Abdelrahman

Completed

Effectiveness of Rotation-advancement and Straight-line Surgical Approaches in Repairing Unilateral Cleft Lip Defect

Unilateral Cleft Lip

Egypt
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Merck Sharp & Dohme LLC

Completed

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Non-alcoholic Fatty Liver Disease
SK Chemicals Co., Ltd.

Completed

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

Overactive Bladder

Korea, Republic of
Yale University
Johns Hopkins University; University of Colorado, Denver; Northwestern University and other collaborators

Recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (PREGnant)

Infertility | Endometriosis

United States
Yale University
University of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaborators

Active, not recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)

Infertility | Endometriosis

United States
Beersheva Mental Health Center

Unknown

Neurofeedback Using TMS as an Assessment Tool

Brain Diseases

Israel

3

Subscribe